RNAZ Stock Analysis: Buy, Sell, or Hold?
RNAZ - TransCode Therapeutics, Inc. Common Stock
$3.00
-0.16 (-5.06%)
▼
5d:
-12.54%
30d:
-64.41%
90d:
-54.55%
WAIT
LOW Confidence
Analysis Updated: Aug 17, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When RNAZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RNAZ is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RNAZ is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNAZ is currently trading at $3.00, which is considered oversold relative to its 30-day fair value range of $3.51 to $7.72.
Technical Outlook: Technically, RNAZ is in a strong downtrend. The price is currently testing key support at $2.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+196.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAZ is in a strong downtrend. The price is currently testing key support at $2.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+196.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.51 -
$7.72
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 196.7% below Wall St target ($10.00)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.51 -
$7.72
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.94
Resistance Level
$4.72
Current Trend
Strong Downtrend
Technical data as of
Aug 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.53
Wall Street Target
$10.00
(+196.7%)
Share & Embed Analysis
Last updated: August 18, 2026 10:19 AM ET
Data refreshes hourly during market hours. Next update: 11:19 AM
Data refreshes hourly during market hours. Next update: 11:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 42 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 47 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 29 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 38 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 59 HOLD |
